Somatotrophin axis hormones in patients affected with psoriasis

Neuroendocrinology Letters

Volumn 26, Issue 6, 2005, Pages 724-728

  Damasiewicz Bodzek, Aleksandra ^a,b   Kos Kudła, Beata ^a   Suwała Jurczyk, Bozena ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Regional Specialist Hospital No 4   (Poland)

Author keywords

Growth hormone (GH); Insulin like growth factor binding protein 3 (IGFBP 3); Insulin like growth factor I (IGF I); Psoriasis; Psoriasis area and severity index (PASI); Somatotrophin axis

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PSORIASIS; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE;

EID: 33644996929     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. www.psorsite.com/docs/pasi.html
2. Weber G, Neidhardt M, Schmidt A, Geiger A. Correlation of growth hormone and aetiology of psoriasis. Arch Dermatol Res 1981; 270:129-140.
3. Weber G, Heitz PU. Cytoendocrinological findings in the pituitary glands of patients with psoriasis. Acta Enclocrinol (Copenh) 1988; 119:501-505.
4. Weber G, Heitz U, Pliess G. Hyperplasia of growth hormone - producing cells in the hypophysis in psoriasis. Study of 10 patients. Hautarzt 1986; 37:458-462.
5. Weber G, Klughardt G, Neidhardt M. Psoriasis and human growth hormone: aetiology and therapy. Arch Dermatol Res 1981; 270:361-365.
6. Weber G, Krughardt G, Neidhardt M, Galle K, Frey H, Geiger A. Treatment of psoriasis with somatostatin. Arch Dermatol Res 1982; 272:31-36.
7. Weber G, Pliess G, Heitz U. Growth hormone producing hyperplasia of pituitary gland in psoriasis. Arch Dermatol Res 1985; 277:345.
8. Guilhou JJ, Boulanger A, Barneon G, Vic P, Meynadier J, Tardieu JC et al. Somatostatin treatment of psoriasis. Arch Dermatol Res 1982;274:249-257.
9. Guilhou JJ. Growth hormone, somatostatin and psoriasis. Dermatologica 1990; 181:81-82.
10. Matt LH, Kingston TP, Lowe NJ: Treatment of severe psoriasis with somatostatin. J Dermatol Treat 1989; 1:3-4.
11. Venier A, De Simone C, Forri L, Ghirlanda G, Uccioli L, Serri F et al. Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res 1988; 280 (suppl): 51-54.
12. Mackie RM, Beastall GM, Thomson JA. Growth hormone levels in psoriasis. Arch Dermatol Res 1983; 275:207-208.
13. Priestley GC, Gawkrodger DJ, Seth J, Going SM, Hunter AA. Growth hormone levels in psoriasis. Arch Dermatol 1984; 276:147-150.
14. Björntorp E, Wickelgren R, Bjarnason R, Swanbeck G, Carlsson LMS, Lindahl A. No evidence for involvement of the growth hormone/ insulin-like growth factor-1 axis in psoriasis. J Invest Dermatol 1997; 109:661-665.
15. Oakes SR, Haynes KM, Waters MJ, Herington AC, Werther GA. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Enclocrinol Metab 1992; 75:1368-1373.
16. Schaller B. Gender-related differences in non-functioning pituitary adenomas. Neuroendocrinol Lett 2003; 24:425-30.
17. Neugebauer D, Weber G. Somatostatin deficiency, hyperinsulinism and thrombocyte aggregation in psoriasis. Z Hautkr 1988; 63:585-590.
18. Hodak E, Gottlieb AB, Anzilotti M, Krueger JG. The insulin-like growth factor 1 receptor is expresses by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. J Invest Dermatol 1996; 106:564-570.
19. Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin-like growth factor I receptor is overexpresses in psioriatic epidermis, but is differentialy regulated from the epidermal growth fector receptor. J Exp Med 1992; 175:1081-1090.
20. Ristow JH. Increased synergistic effect of EGF and IGF-I on DNA synthesis of cultured psoriatic keratinocytes. Dermatology 1997; 195:213-219.
21. Nickoloff BJ, Misra P, Morhenn VB, Hintz RL, Rosenfeld RG. Plasma somatomedin C levels in psoriasis. Br J Dermatol 1987; 116:15-20.
22. Ristow HJ. Effect of insulin-like growth factor-1 (Somatomedin-C) on thymidine incorporation in cultured psoriatic keratinocytes after growth arrest in growth factor-free medium. Growth Regul 1993; 3:129-137.
23. Xu S, Cwyfan-Hughes SC, van der Stappen JWJ, Sansom J, Burton JL, Donnelly M et al. Altered insulin-like growth factor-II (IGF-II) level and IGF-binding protein-3 (IGFBP-3) protease activity in interstitial fluid taken from the skin lesion of psoriasis. J Invest Dermatol 1996; 106:109-112.
24. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen R The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-1 receptor gene. Mol Endocrinol 1995; 9:361-367.
25. Wraight CJ, Edmondson SR, Fortune DW, Varigos G, Werther GA: Expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in the psoriatic lesion. J Invest Dermatol 1997; 108:452-456.
26. Marek B, Kajdaniuk D, Borgiel-Marek H, Kos-Kudla B, Ostrowska; Z, Banas I et al. Function of the growth hormone axis - insulin-like growth factors - insulin-like growth factor binding proteins in patients with chronic liver diseases. Pol Merkuriusz Lek 2001; 10:185-190.
27. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuroenclocrinol Lett 2003; 24:21-27.